Logo image of EPRX

EUPRAXIA PHARMACEUTICALS INC (EPRX) Stock Fundamental Analysis

NASDAQ:EPRX - Nasdaq - CA29842P1053 - Common Stock - Currency: USD

3.94  -0.03 (-0.76%)

Fundamental Rating

3

EPRX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. While EPRX has a great health rating, there are worries on its profitability. EPRX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

EPRX had negative earnings in the past year.
EPRX had a negative operating cash flow in the past year.
In the past 5 years EPRX always reported negative net income.
EPRX had a negative operating cash flow in each of the past 5 years.
EPRX Yearly Net Income VS EBIT VS OCF VS FCFEPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -89.70%, EPRX is not doing good in the industry: 73.30% of the companies in the same industry are doing better.
The Return On Equity of EPRX (-91.67%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -89.7%
ROE -91.67%
ROIC N/A
ROA(3y)-100.7%
ROA(5y)-130.32%
ROE(3y)-510.2%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EPRX Yearly ROA, ROE, ROICEPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

EPRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EPRX Yearly Profit, Operating, Gross MarginsEPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

EPRX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, EPRX has more shares outstanding
There is no outstanding debt for EPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EPRX Yearly Shares OutstandingEPRX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
EPRX Yearly Total Debt VS Total AssetsEPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

EPRX has an Altman-Z score of 127.22. This indicates that EPRX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of EPRX (127.22) is better than 99.28% of its industry peers.
There is no outstanding debt for EPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 127.22
ROIC/WACCN/A
WACCN/A
EPRX Yearly LT Debt VS Equity VS FCFEPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

EPRX has a Current Ratio of 13.00. This indicates that EPRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 13.00, EPRX belongs to the top of the industry, outperforming 84.77% of the companies in the same industry.
A Quick Ratio of 13.00 indicates that EPRX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 13.00, EPRX belongs to the best of the industry, outperforming 84.77% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13
Quick Ratio 13
EPRX Yearly Current Assets VS Current LiabilitesEPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.83% over the past year.
EPS 1Y (TTM)17.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.60% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y5.38%
EPS Next 2Y28.45%
EPS Next 3Y26.46%
EPS Next 5Y14.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPRX Yearly Revenue VS EstimatesEPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
EPRX Yearly EPS VS EstimatesEPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EPRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EPRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EPRX Price Earnings VS Forward Price EarningsEPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EPRX Per share dataEPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as EPRX's earnings are expected to grow with 26.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.45%
EPS Next 3Y26.46%

More info and screens

0

5. Dividend

5.1 Amount

EPRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EUPRAXIA PHARMACEUTICALS INC

NASDAQ:EPRX (6/5/2025, 4:00:27 PM)

3.94

-0.03 (-0.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)N/A N/A
Inst Owners13.09%
Inst Owner ChangeN/A
Ins Owners22.83%
Ins Owner ChangeN/A
Market Cap141.25M
Analysts85
Price Target7.52 (90.86%)
Short Float %0.57%
Short Ratio11.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-51.96%
Min EPS beat(2)-80.04%
Max EPS beat(2)-23.87%
EPS beat(4)2
Avg EPS beat(4)-22.22%
Min EPS beat(4)-80.04%
Max EPS beat(4)12.99%
EPS beat(8)5
Avg EPS beat(8)-12.56%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.19%
PT rev (3m)-17.83%
EPS NQ rev (1m)-21.61%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-40.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.94
P/tB 4.94
EV/EBITDA N/A
EPS(TTM)-1.05
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-0.84
FCFYN/A
OCF(TTM)-0.83
OCFYN/A
SpS0
BVpS0.8
TBVpS0.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -89.7%
ROE -91.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-100.7%
ROA(5y)-130.32%
ROE(3y)-510.2%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 196.46%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13
Quick Ratio 13
Altman-Z 127.22
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)106.53%
Cap/Depr(5y)142.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.36%
EPS Next Y5.38%
EPS Next 2Y28.45%
EPS Next 3Y26.46%
EPS Next 5Y14.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y48.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.14%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-41.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.87%
OCF growth 3YN/A
OCF growth 5YN/A